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ABSTRACT  
The demand for liver transplantation exceeds supply with rising waiting list mortality. 
Utilisation of high-risk organs is low and a substantial number are discarded. We 
report the first series of five transplants with “discarded” livers following viability 
assessment by normothermic machine liver perfusion (NMLP). The testing protocol 
consisted of perfusate lactate, bile production, vascular flows and liver appearance. 
All livers were exposed to a variable period of static cold storage prior commencing 
NMLP. Four organs were recovered from donors after circulatory death and discarded 
due to prolonged donor warm ischaemic times; one liver from brain death donor was 
declined for very high liver function tests. The median (range) total graft preservation 
time was 798 (724-951) minutes. The transplant procedure was uneventful in every 
recipient with immediate function in all grafts. The median in-hospital stay was 10 (6-
14) days. At present, all recipients are well, with normalised liver function tests at 
median follow-up of 6 (5-18) months. High-risk grafts viability assessment provides 
specific information on liver function can permit their transplantation without 
compromising recipient safety. This novel approach may substantially increase organ 
availability for liver transplantation.  
 
 
 
 
 
 
  
INTRODUCTION  
Deaths from liver disease have soared by 40% in the last decade, killing 11,000 a year 
in England at an average age of 59 years (1). Liver transplantation (LT) is highly 
successful in treating end-stage disease, but access is restricted by the number of 
available organs and approximately 20% of patients die whilst awaiting 
transplantation (2-5). To address this, more transplants are performed using high-risk 
organs, from donors with co-morbidities or relative contraindications (6-9). These 
organs, termed “marginal” or “extended criteria” grafts, are more susceptible to cold 
ischaemia, and have an increased risk of graft failure, recipient morbidity and 
mortality (7, 10). The devastating consequences of graft failure following LT preclude 
greater utilisation of high-risk livers. For example, in 2014-15, of 1282 identified UK 
donors, only 924 (72%) livers were deemed suitable for retrieval and 812 (63%) were 
subsequently transplanted (2). Data from the United States are similar and the latest 
report of the Organ Procurement and Transplant Network showed that only 
6312/8144 (73%) potential donor livers were transplanted (3). Nevertheless, over the 
same period more than 3200 patients died or were removed from the transplant 
waiting list in these countries, for being too sick for transplantation (3, 11). 
 
Normothermic machine liver perfusion (NMLP) is a novel technique, substituting the 
detrimental effect of static cold storage (SCS) by preserving the organs in near-
physiological conditions, with oxygen and nutrients at 37°C. The preserved metabolic 
activity at normothermia not only prevents further graft damage caused by ischaemia, 
but allows ex-situ monitoring of liver function by permitting objective assessment of 
liver biochemistry, blood flow and bile production.  The complexity of dual - arterial 
and portal - liver inflow has proved technically challenging. The first machine 
introduced to clinical practice recently was developed by the Oxford group, and was 
used for the pilot liver transplant series using standard criteria organs preserved by 
NMLP, completely avoiding SCS (12). Pre-clinical studies on “discarded” livers 
showed that bile production, in combination with maintenance of physiological pH, 
metabolism of lactate and stable blood flow rates, are sensitive parameters predictive 
of graft viability and in August 2014 our group carried out the first-in-man transplant 
of such a liver graft (13). Here, we present the first five recipients of NMLP treated 
“discarded” liver allografts. 
 
METHODS 
Study design 
This series evolved from a research project of viability testing of “discarded” human 
allografts where NMLP based viability criteria were established and a perfusion fluid 
was developed to facilitate resuscitation of high-risk organs. After defining viability 
criteria, we obtained approval from the hospital ethics and novel therapeutic 
committees in June 2014 to perform a pilot series of five clinical transplants. Here we 
present the results of six consecutive NMLPs, commenced with an intention to 
perform clinical transplantation in carefully selected and consented adults with grafts 
that met viability criteria. 
 
Source of “discarded” human livers 
Based on donor history and laboratory results, the livers (except donor four with a 
progressively rising liver tests) were initially accepted and procured by one of the 
teams from the UK National Organ Retrieval Service, using a nationally agreed 
surgical protocol, with the intention of transplantation (14). All grafts were initially 
preserved in University of Wisconsin preservation fluid at 4oC.  
On arrival at the transplanting centre, each liver was assessed and deemed unsuitable 
by the consultant surgeon. The liver was then offered to and turned down by all UK 
liver transplant centres and then offered for use in our pilot study by the NHSBT co-
ordinating office. Ethical approval for the study was granted by University Hospital 
Birmingham NHS Foundation Trust Novel Therapeutics and NHSBT Ethics 
Committees.  
To ensure safety, risks were minimised by excluding livers with a significant pre-
existing disease, and all grafts in this study met the following inclusion criteria: 
maximum donor age of 65 years, cold ischaemic times (CIT) less than 16 hours for 
livers from donors after brain death (DBD), or less than 10 hours from donors after 
circulatory death (DCD), donor warm ischaemic time (systolic blood pressure less 
than 50mmHg to aortic perfusion) in DCD organs less than 60 minutes, absence of 
hepatitis B, hepatitis C, or human immunodeficiency virus infection, and a 
macroscopic appearance without fibrosis or cirrhosis.  
 
Clinical protocol for “discarded” liver grafts viability testing 
Graft preparation was analogous to the standard back-table procedure, and the portal 
vein was dissected and cannulated. The coeliac trunk branches were ligated and the 
hepatic artery was dissected to the gastroduodenal artery. If present, accessory left 
and/or right arteries were preserved and an iliac artery interposition graft was attached 
to the aortic patch. The arterial cannula was placed in a way it did not reach the vessel 
area used subsequently to perform the anastomosis during the graft implantation 
procedure.  
NMLP was then commenced, using Liver Assist (Organ Assist, the Netherlands) or 
OrganOx Metra (OrganOx, UK) devices. Organ viability was assessed within three 
hours of perfusion. A viable graft had to produce bile or the perfusate lactate level had 
to be less than 2·5 mmol/L, in combination with at least two of the following three 
criteria: 1) perfusate pH greater than 7.30, 2) stable arterial flow of more than 150 mL 
and portal venous flow more than 500 mL per minute respectively, and 3) 
homogeneous graft perfusion with soft consistency of the parenchyma.  
 
Histology 
Menghini liver biopsies were obtained at three time points: 1) preNMLP, 2) at the end 
of NMLP, and 3) following reperfusion of the implanted liver. The cut end of the 
common bile duct was obtained post-NMLP. All biopsies were placed in formal 
saline and processed by standard procedures to a paraffin block.  Sections stained 
with Haematoxylin and Eosin (H&E) and Periodic Acid Schiff (PAS) were examined 
for the per cent of large droplet (ld) and small droplet (sd) macrovesicular steatosis 
(MS), hepatocyte necrosis and glycogen depletion. Preservation-reperfusion injury in 
post-reperfusion biopsies was graded based on these features together with neutrophil 
infiltration. Bile duct biopsies were assessed for loss of the lining epithelium, 
epithelial damage in superficial and deep peribiliary glands, stromal necrosis, 
arteriolar necrosis and thrombosis according to previously published criteria (15). 
 
Transplant recipients 
The recipients were patients listed for transplantation at Queen Elizabeth Hospital 
(Birmingham, UK). All patients received an explanation about the principles of 
NMLP during consenting for LT. When a recovered viable liver graft became 
available, the consultant surgeon familiar with the project re-explained the procedure 
in detail and obtained patient’s additional consent to accept the “resuscitated” graft. 
Recipients considered for this study had low surgical perioperative risk as assessed by 
the multi-disciplinary team during the listing process. Patients with hepatocellular 
carcinoma, with a high risk of waiting list dropout due to tumour progression, were 
regarded as favourable recipients.  
 
Liver transplant procedure and patients follow up 
The grafts were implanted with the vena cava preserving technique. After completing 
the native liver hepatectomy, the NMLP was stopped and the graft was flushed with 2 
litres of cold Histidine-Tryptophan-Ketoglutarate solution, vascular and bile duct 
cannulas were removed and bile duct and liver biopsies were taken. The graft was 
immediately implanted and reperfused in the standard manner. The perioperative data, 
post-transplant laboratory results and patient recovery course were collected. 
Following discharge from the hospital, patients were reviewed on the outpatient clinic 
with weekly (1st month) and the fortnightly (2nd to 3rd month) frequency.    
 
Funding source 
The project was funded by University Hospital Birmingham Liver Charities. The 
Organ Assist (n=5 livers) and OrganOx Metra (n=1) devices used were on loan and 
neither of the two manufacturers had any role in the study design, data collection, 
analysis, interpretation or the manuscript preparation. The authors are employees of 
the University Hospital Birmingham or University of Birmingham and none of them 
received any payment or have any conflict of interest related to this manuscript. 
 
RESULTS 
The median donor age was 49 (range 29-54) years. Four livers were recovered from 
DCD and two from DBD donors. There was an even split between the liver offers 
initially accepted and retrieved by our team versus other teams. The median SCS time 
was 422 (387-474) minutes. Five out of six livers met the viability criteria and were 
used for transplantation. The detailed demographics and graft characteristics are 
provided in Table 1. 
 
Donor history details and reasons for initial graft discard 
Donor one (DCD) was a 29-year-old diabetic male admitted with cardiac arrest, 
having marginally elevated liver function tests (LFTs). Aortic in-situ perfusion was 
commenced 112 minutes following withdrawal of treatment (WoT), with a patchy 
graft appearance. Liver was rejected due to prolonged donor warm ischaemic time 
(dWIT) and poor perfusion. 
Donor two (DBD) was a 69-year-old male ventilated for 27 days following surgery 
for ascending aorta dissection, with a peak alanine transaminase (ALT) of 2264 UI/L 
and multiple cardiac arrests. The liver was rejected based on history and LFTs. 
Donor three (DCD) was a 49-year-old female with body mass index (BMI) 45 kg/m2 
with a history of hypertension, depression with two paracetamol suicide attempts, 
deep vein thrombosis with an infected chronic ulcer. The liver was rejected due to the 
prolonged dWIT in combination with high BMI suggesting significant steatosis.  
Donor four (DBD) was a 54-year-old female with an intracranial bleed post-resection 
of a suprasellar meningioma. Because of rising LFTs (ALT 997 UI/L on day of 
donation), the liver was not accepted.  
Donor five (DCD) was a 46-year-old male who collapsed with 40 minutes cardiac 
arrest. He was a known heavy drinker and the admission ALT was 1297 UI/L. The 
graft was rejected due to its large size of 2486g and abnormal LFTs.  
Donor six (DCD) was a 51-year-old male with intracranial haemorrhage, diabetes on 
metformin and BMI 33 kg/m2. The graft was rejected due to large size (2522g), and 
steatotic appearance on macroscopic assessment. 
 
Viability testing  
All but one graft met defined criteria for viability and showed signs of function as 
assessed by the perfusate lactate clearance and bile production. The median starting 
lactate level was 9.9 mmol/L that decreased in two hours to the median level 1.5 
mmol/L. The median NMLP time was 332 (318-564) minutes. The total preservation 
time of the transplanted livers was 798 (724-951) minutes.  
Graft 2 did not meet viability criteria, showing initially a rapid lactate clearance with 
levels decreasing from 11.4 mmol/L to 2.1 mmol/L within two hours of perfusion. 
The liver had aberrant arterial anatomy, with an accessory right hepatic artery rising 
from superior mesenteric artery. Despite a presence of back flow bleeding from the 
artery stump after graft connection to the device, there was noticeable colour 
difference on the liver surface after 90 minutes of perfusion, prompting arterial 
reconstruction. Following re-established inflow via the accessory artery, lactate levels 
rose and did not normalise within the three hour time frame, and the liver was 
“discarded”. Details of the NMLP parameters, graft function, and transplantation 
procedure are provided in Table 1. 
 
Histological findings 
No significant large droplet steatosis was seen in these livers, with the majority (4/6) 
also having neglible sdMS and two having mild (<33%) sdMS (Figure 2A,B).  
Hepatocyte necrosis (Figure 2C,D) of more than just a few cells was present in one 
liver which was transplanted (30% increasing to 50% post-transplant), and in the one 
which did not reach transplant criteria (15% hepatocyte loss from necrosis at an 
earlier time point). In 4/5 of the transplanted livers glycogen stores appeared to be 
replenished during NMLP (Figure 2E,F). The injury post-transplant varied from mild 
to severe.   
Bile duct injury (Figure 3) was generally mild: there were only mild epithelial 
changes in deep peribiliary glands.  One post-NMLP bile duct biopsy showed mild 
and two moderate stromal nuclear loss. Minimal arteriolar necrosis was only seen in 
one of the post-NMLP biopsies. Thrombosis was not seen. The detailed findings are 
provided in Table 2. 
 
Patient outcomes  
The median recipient age was 56 (47-66) years. The transplantation procedure was 
uneventful for every recipient with immediate function recovery in all grafts. The 
median intensive therapy unit (ITU) stay was 3 (2-6) days, with one early 
readmission, in a patient who developed acute coronary syndrome 8 days following 
surgery, requiring percutaneous coronary angioplasty with stent insertion. The median 
in-hospital stay was 10 (6-15) days. To date, all patients are well, with normalised 
liver tests at a median follow-up of 6 (5-18) months. The recipient demographics and 
outcome details are provided in Table 3. 
 
DISCUSSION 
The consequences of transplanting a liver, which fails to function, are potentially dire. 
NMLP offers the opportunity to assess and improve the quality of high-risk livers 
deemed unsuitable for transplantation.  To our knowledge this report describes the 
first patient series of “discarded” liver allografts transplanted following successful 
assessment and resuscitation by NMLP. This pilot study shows that a substantial 
proportion of high-risk donor livers might be transplanted by subjecting them to 
viability testing during NMLP, without compromising patient safety in a cohort of 
low risk recipients.  
 
Since transplantation was established as a highly successful treatment almost half a 
century ago, scarcity of suitable donors has become a worldwide factor limiting 
access to this treatment. On-going medical advancement, ranging from the improved 
management of intracranial vascular malformations to the vast improvements in road 
traffic safety, has had an impact on decreasing the availability of DBD organ donors. 
National and international regulatory bodies have proposed strategies and have 
identified funding to overcome the shortage, but these are largely based on increasing 
the number of extended criteria organs, known to be associated with a higher risk for 
the recipient (16).  
 
Machine perfusion technology has shown promising results in preserving 
cardiothoracic and abdominal organs (17-22). Although most of the reported series 
showed its feasibility in organs acceptable for transplantation, the technology has 
already demonstrated the potential to expand the donor pool. For example, the team at 
St Vincent’s Hospital in Sydney recently reported a series of heart transplants using 
allografts recovered from donors after circulatory death that were previously deemed 
unfeasible (18). 
 
Normothermic perfusion replicating near-physiological conditions ex-vivo has for 
long time been regarded as the optimal machine perfusion strategy. It has required 
advanced technology that was previously not available. Several groups have 
successfully pursued simpler hypothermic machine perfusion (HMP) (19, 23, 24). The 
early adoption of HMP was also facilitated by the negligible risk of graft loss related 
to potential device malfunction. Clinical trials of hypothermic machine perfusion of 
kidneys have demonstrated improved results in renal transplantation (21, 25). 
Numerous teams have reported encouraging outcomes following hypothermic liver 
perfusion, however the first reported high-risk graft series demonstrated a high 
incidence of biliary complications and also observed primary non-function (19, 26).  
 
The devastating consequences of primary graft non-function in cardiothoracic and 
liver transplantation preclude further extension of organ acceptance criteria. The 
utilisation of high-risk hearts or lungs is only 30-40%, which might relate to the use 
of ventricular assist devices and extracorporeal membrane oxygenation as a bridge to 
transplantation, allowing patients to be kept alive until a lower risk donor becomes 
available. In contrast, the constant growth in demand for liver transplants has 
extended utilisation of marginal livers to 70-80%, often compromising post-transplant 
outcomes and patients’ safety (7, 10).  
 
The limits in the utilisation of high-risk livers have been explored in countries such as 
the UK, where these organs can be allocated to lower risk recipients (27, 28). The 
protocol presented here may transform use of high-risk livers worldwide. Diminishing 
the risk of primary non-function or severe dysfunction, with their often-fatal 
consequences, might allow further evolution of this novel approach and permit safe 
allocation of high-risk organs to the sickest recipients, benefiting the patients with the 
highest waiting list mortality (29). 
 
In this series, livers were declined by all the UK transplant units, after which NMLP 
commenced with a variable period of static cold storage. Still, five out of six tested 
grafts were viable. Recovering 80% of the unutilised organs would allow over 2000 
additional liver transplantations in the UK and US alone. Although we envisage that 
viability testing will transform the organ selection and acceptance process and shift 
boundaries in using high-risk organs, our observation focuses only on feasibility and 
short-term outcome. Five months follow up of the last included transplant in this 
series, in combination with normal LFTs in all included patients is likely to exclude 
any early clinically relevant form of ischaemic type biliary complication, one of the 
main problems in recipients of DCD livers (30). The histology of the post-NMLP 
common bile duct biopsy is also not suspicious for the development of ischaemic bile 
duct lesions with less than 50% epithelial necrosis of deep peribiliary glands, no 
thrombi and minimal arteriolar necrosis (15). Other potential limitations could be the 
additional costs and challenges of wider implementation of NMLP technology and 
expertise, but this may be justified by the increases in transplant activity and 
improved organ utilisation. In addition, our study shows the feasibility to perform 
NMLP following SCS and inspection at the transplant centre, with logistical and 
financial advantages, and may allow targeting livers that would benefit most from 
NMLP. 
   
This report demonstrates that a substantial proportion of currently “discarded” liver 
allografts might be salvaged by subjecting them to NMLP and viability testing. Use of 
this technology can transform the utilisation of high-risk organs and may improve 
access to treatment for thousands of patients awaiting liver transplantation globally.  
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Table 1. Donor demographics, graft characteristics and machine perfusion data 
Donor number Donor 1 (transplant 1) 
Donor 2 
(discarded
) 
Donor 3 
(transplant 2) 
Donor 4 
(transplant 3) 
Donor 5 
(transplant 4) 
Donor 6 
(transplant 5) 
Age 29 69 49 49 46 51 
Donor type DCD DBD DCD DBD DCD DCD 
Sex Male Male Female Female Male Female 
Height (cm) 173 174 169 161 179 165 
Bodyweight (kg) 75 94 130 52 90 90 
Body mass index (kg/m2) 25 31 45 20 28 33 
Pre-morbid cardiac arrest  
(downtime minutes) 
Yes 
(58) 
Yes 
(multiple) 
Yes 
(35) No 
Yes 
(40) No 
Liver function tests Elevated Very high1 Normal Very high2 Very high3 Normal 
Days on ventilator 8 5 2 7 6 2 
Co-morbidities and history 
Diabetes 
mellitus (type 
1) 
Bladder 
cancer 
(recent 
surgery) 
hypertensi
on 
Paracetamol 
overdoses, 
DVT 
hypertension 
Suprasellar 
meningioma 
(recent 
surgery) 
Alcohol 
misuse 
Diabetes 
mellitus (type 
2) hypertension 
Cause of death Hypoxic brain injury 
Hypoxic 
brain 
injury 
Hypoxic 
brain injury 
Intracranial 
haemorrhage 
Hypoxic 
brain injury 
Intracranial 
haemorrhage 
Liver weight (g) 1997 2400 1943 1382 2486 2522 
Donor warm ischaemic time  
(minutes) 109 NA 36 NA 31 19 
Cold ischaemic time 
(minutes) 422 518 406 387 453 474 
Donor risk index 2.31 1.97 2.36 1.83 2.25 3.03 
Graft offering4 Fast-Track Full offer Full offer Fast-track Fast-track Fast-track 
Retrieval team and 
location5 Regional 
6 Regional Regional Extra-zonal Extra-zonal Extra-zonal 
Reason for discard 
Long dWIT, 
poor liver 
flush 
High 
LFTs, 
biopsy 
findings 
Long dWIT, 
donor history, 
BMI 
High LFTs, 
macroscopic 
appearance 
Long dWIT, 
macroscopic 
appearance 
Macroscopic 
appearance 
Lactate (mmol/L)       
Highest 13.3 11.4 5.5 13.1 12.4 13.9 
Lowest 0.7 2.1 1.4 2.2 1.2 0.9 
Last 0.7 4.5 1.4 2.4 1.2 2.8 
Total Bile production (g) 23.2 6.1 0.0 18.5 11.3 0.0 
Mean Arterial flow 
(mL/min) 656 549 529 682 772 360 
Perfusion time (min) 416 255 318 564 345 305 
Total preservation time 
(min) 838 773 724 951 798 779 
Transplanted Yes No Yes Yes Yes Yes 
       
Lactate peak / end of 
surgery (mmol/L) 7.0 / 4.5 NA 4.3 / 3.0 4.0 / 2.9 5.0 / 3.3 3.6 / 1.4 
       
Abbreviation 
ALT=alanine transferase. BMI=body mass index. DVT=deep vein thrombosis. UHB=University Hospitals Birmingham; 
DBD=donor after brain death. DCD=donor after circulatory death. NA=not applicable. dWIT=donor warm ischaemic time. 
LFTs=liver function tests. 
Note 
1ALT 2264 IU/L post cardiac arrest, reducing to 883 IU/L at time of retrieval. 2 ALT progressively rising to 997 IU/L at the time 
of retrieval. 
3ALT 1297 IU/L post cardiac arrest, reducing to 257 IU/L at time of retrieval. 4 fast-track offers denotes the liver was offered 
following refusal by other teams, often after it was procured and inspected by the retrieval team. 5 regional liver procurements 
were performed by the UHB team, with the expected travel time back to the hospital less than 3 hours, extra-zonal procurements 
were performed by other teams, with the expected shipment time greater than 3 hours. 6 expected travel time greater than 4 hours. 
  
Table 2. Histological features on liver biopsies 
 
Donor 1 
(transplant 1) 
Donor 2 
(discarded) 
Donor 3 
(transplant 2) 
Donor 4 
(transplant 3) 
Donor 5 
(transplant 4) 
Donor 6 
(transplant 5) 
 
Large droplet macrovesicular steatosis1 
Pre-NMLP nil NA NA nil <5% nil 
Post-NMLP nil nil nil <5% <5% nil 
Post-
reperfusion nil NA nil <5% <5% nil 
Small droplet macrovesicular steatosis2 
Pre-NMLP <5% NA NA 20% 20% <5% 
Post-NMLP <5% 30% <5% <5% 20% nil 
Post-
reperfusion nil NA 10% <5% 25% 10% 
Necrosis3 
Pre-NMLP nil NA NA 5% nil nil 
Post-NMLP 1% 15% (old) 5% nil 30% nil 
Post-
reperfusion 1% NA 10% 1% 50% 5% 
Glycogen depletion4 
Pre-NMLP moderate-severe  moderate minimal severe mild-moderate 
Post-NMLP mild severe mild-moderate moderate-severe mild nil 
Post-
reperfusion moderate NA moderate-severe moderate moderate-severe moderate-severe 
Post-reperfusion injury 
 mild NA moderate moderate severe moderate-severe 
Abbreviation 
NMLP=normothermic machine liver perfusion. NA=not applicable / available 
Note 
1 large droplet macrovesicular steatosis is defined as a single large fat droplet within the hepatocyte cytoplasm displacing the nucleus. Mild <1/3, 
moderate 1/3-2/3 and severe>2/3 of hepatocytes contain large droplet macrovesicular fat. 
2Small droplet macrovesicular steatosis is defined as fat droplets, usually multiple within the cytoplasm of the hepatocyte which do not displace the 
nucleus. Mild <1/3, moderate 1/3-2/3 and severe>2/3 of hepatocytes contain small droplet macrovesicular fat. 
3Necrosis is depicted as the percent of total hepatocytes in the biopsy which are necrotic. 
4Glycogen depletion is graded as mild -up to 20% of non-necrotic hepatocytes do not contain PAS positive glycogen, moderate 20-95% of 
hepatocytes do not contain glycogen and severe >95% of hepatocytes do not contain glycogen. 
 
 
  
Table 3. Recipient demographic and outcomes 
 Recipient 1 
(donor 1) 
Recipient 2 
(donor 3) 
Recipient 3 
(donor 4) 
Recipient 4 
(donor 5) 
Recipient 5 
(donor 6) 
Age at transplant 
(years) 46 56 66 65 56 
Sex Male Male Male Male Female 
Primary etiology Alcohol NAFLD Alcohol and NAFLD 
Haemo-
chromatosis Alcohol 
Indication for transplant Encephalopathy Refractory ascites HCC HCC 
Refractory 
ascites 
MELD at LT 17 9 7 7 8 
UKELD at OLTx 55 49 51 47 51 
Waiting list time 
(months) 2 6 7 1 3 
ITU stay (days) 5 2 3 6 3 
Early allograft 
dysfunction 1 No No No No No 
Renal replacement 
therapy No No No Yes (10 days) No 
In hospital stay (days) 12 7 6 15 10 
Early complications nil nil nil 
Myocardial 
requiring PCI 
and stent 
nil 
Liver function tests 
Peak ALT (IU/L) 1215 1188 1879 1408 1242 
Peak bilirubin 110 100 124 87 167 
At 1 month 
ALT (IU/L) 
Bili (µmol/L) 
ALP (IU/L) 
 
24 
15 
73 
 
17 
6 
113 
 
43 
13 
114 
 
38 
8 
178 
 
6 
13 
64 
At 3 months 
ALT (IU/L) 
Bili (µmol/L) 
ALP (IU/L) 
 
16 
15 
135 
 
21 
6 
103 
 
29 
10 
79 
 
8 
5 
63 
 
10 
21 
81 
Creatinine (µmol/L) 
At 1 month 
At 3 months 
 
90 
82 
 
67 
77 
 
78 
98 
 
168 
147 
 
62 
92 
Abbreviation 
HCC=hepatocellular carcinoma. MELD=model for end-stage liver disease. UKELD=UK model for end-stage liver disease score. 
NAFLD=non-alcoholic fatty liver disease; LT=liver transplantation. ALP=alkaline phosphatase. ALT=alanine transferase. 
AST=aspartate transferase; Bili=Bilirubin. ITU=intensive treatment unit. LFT’s=liver function tests. PCI=percutaneous coronary 
intervention. 
Note 
1 Early allograft dysfunction consists of presence one or more of the following variables: (1) bilirubin 10 mg/dL on postoperative 
day 7; (2) INR 1·6 on postoperative day 7; (3) aminotransferase level (alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST]) >2000 IU/mL within the first 7 postoperative days (Olthoff et al, Liver Transplantation, 2010) 
 
  
 
 
 
FIGURE LEGENDS 
Figure 1: Viability assessment by the perfusate lactate clearance and the post-
transplant liver function tests 
Panel A shows the lactate clearance during the normothermic perfusion. All livers 
demonstrated metabolic activity and perfusate lactate levels dropped below 3.0 
mmol/L. In liver number 2 the lactate levels did not decrease below 2.5 mmol/L but 
started to rise after 150 minutes. The organ failed to meet the viability criteria and 
was not used for transplantation. Panel B shows the post-transplant changes in the 
ALT levels, the enzyme is often used as a surrogate marker for the preservation 
related liver injury. The initial post-transplant levels were similar in all livers with 
progressive improvement within the first post-transplant week. In all recipients the 
ALT levels were normal by one month following the transplantation. Panel C 
demonstrates similar improvement pattern if bilirubin levels. In the recipient number 
one bilirubin levels slightly increased later during the follow up and the magnetic 
cholangiography performed at 6 months post-transplant revealed mild anastomotic 
biliary stricture. The bilirubin level normalised with a conservative management with 
ursodeoxycholic acid medication.  
 
Figure 2: Histological findings in liver biopsies 
Panels A and B show pre-NMLP haematoxylin and eosin (H&E) stained biopsies 
from liver number 5. Panel A shows negligible large droplet macrovesicular steatosis 
(10x objective). Panel B is a higher magnification showing small droplet 
macrovesicular steatosis involving roughly 20-30% of the hepatocytes. This is seen 
within the circled area as tiny white holes in the hepatocytes. This type of steatosis, 
often referred to as microvesicular steatosis, is not considered to be important in 
determining the amount of fat in an assessment for transplantation. None of the livers 
had more than 5% large droplet steatosis, the type which determines suitability for 
transplantation (20x objective). Panels C and D demonstrate areas of necrosis seen as 
the pale pink hepatocytes (arrows) in post-NMLP biopsies from liver number 5. Panel 
C shows approximately 30% necrosis in the pre-implantation biopsy.  Panel D shows 
an increase in the number of necrotic hepatocytes in the post-reperfusion biopsy, 
approximating to 50% of the liver parenchyma. This liver showed the most necrosis 
in this presented series, this degree of necrosis is considered unfavourable by 
currently used assessment standards. The additional information provided by the 
functional assessment using the normothermic perfusion confirmed the liver viability 
and the graft was successfully transplanted with immediate intraoperative recovery of 
the function and good patient recovery (both sections H&E, 10x objective). Panels E 
and F are Periodic Acid Schiff stained sections of biopsies from liver number 1 in 
which glycogen in hepatocytes stains dark pink. Panel E shows the pre-NMLP biopsy 
with moderate glycogen depletion. Panel F shows the post-NMLP biopsy with 
increased glycogen content, now amounting to only mild depletion (both 10x 
objective). 
 
Figure 3: Bile duct histology 
Figure demonstrates H&E stained sections of bile duct. Double arrowhead shows the 
surface epithelial lining and single arrowhead points at a deep peribiliary plexus. 
Panel A shows the surface epithelium is intact in this part of the bile duct with 
relatively mild changes to the deep peribiliary glands in liver number 6. Panel B 
displays partial surface epithelial loss with well-preserved peribiliary glands in liver 
4. Panel C shows another fragment of bile duct from liver 6 in which there is 
moderately extensive loss of surface epithelium, with stromal nuclear loss deep to the 
double arrowhead, the deep peribiliary glands in this area look moderately injured  
(all 10x objective). 
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